OK-432 develops CTL and LAK activity in mononuclear cells from regional lymph nodes of lung cancer patients

International Journal of Immunopharmacology

Volumn 20, Issue 8, 1998, Pages 375-388

  Takahashi, K ^a   Harauchi, D ^a   Kimura, S ^a   Saito, S ^a   Monden, Y ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

IL 2; Lung cancer; Lymph nodes; OK 432

Indexed keywords

HLA DR ANTIGEN; PICIBANIL; RECOMBINANT INTERLEUKIN 2;

ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUNG CANCER; LYMPH NODE; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HLA-DR ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; LUNG NEOPLASMS; LYMPH NODES; MALE; MIDDLE AGED; PHENOTYPE; PICIBANIL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032412510     PISSN: 01920561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0192-0561(98)00011-3     Document Type: Article

References (39)

1. Barth, R. J., Buck, S. N., Mule, J. J., & Rosenberg, S. A. (1990). Unique murine tumor associated antigens identified by tumor infiltrating lymphocytes. J. Immunol., 144, 1531-1537.
2. Blanchard, D. K., Michelini-Norris, M. B., Friedman, H., & Djeu, J. Y. (1989). Lysis of mycobacteria-infected monocytes by IL-2-activated killer cells: role of LFA-1. Cell Immunol., 119, 402-411.
3. Boccoli, G., Masciulli, E. M., Ruggeri, P., Carlini, P., Giannella, G., Montesoro, G., Mastroberardino, G., Isacchi, G., Testa, U., Calabresi, F., & Peschle, C. (1990). Adoptive immunotherapy of human cancer: The cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatments. Cancer Res., 50, 5795-5800.
4. Dugan, M., Oratz, R., Speyer, J., Roses, D. F., Harris, M. N., Golomb, F., & Bystryn, J. C. (1987). Relationship between immune responses to melanoma vaccine immunization and tumor progression in man. Clin. Res., 35, 523a.
5. Ettinghausen, S. E., Lipford, S. H., Mule, J. J., & Rosenberg, S. A. (1985). Systemic administration of recombinant interleukin-2 stimulates in vivo lymphoid cell proliferation in tissues. J. Immunol., 135, 1488-1497.
6. Fellous, M., Nir, U., Wallach, D., Merlin, G., Rubinstein, M., & Revel, M. (1982). Interferon-dependent induction of mRNA for the major histocompatibility antigens inhuman fibroblasts and lymphoblastoid cells. Proc. Natl. Acad. Sci. U.S.A., 79, 3082-3086.
7. Gaffen, S. L., Lai, S. Y., Ha, M., Liu, A., Hennighausen, L., Greene, W. C., & Goldsmith, M. A. (1996). Distinct tyrosine residues within the interleukin-2 receptor beta chain drive signal transduction specificity, redundancy, and diversity. J. Biol. Chem., 271, 21381-21390.
8. Giacomini, P., Fraioli, R., Calabro, A. M., DiFilippo, F., & Natali, P. G. (1991). Class I major histocompatibility complex enhancement by recombinant leukocyte interferon in the peripheral blood mononuclear cells and plasma of melanoma patients. Cancer Res., 51, 642-656.
9. Gohring, B., Riemann, D., Rebmann, U., Heynemann, H., Schabel, J., & Langner, J. (1996). Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FU. Urol. Res., 24, 297-303.
10. Greenberg, P. D. (1991). Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol., 49, 281.
11. Grimm, E. A., Mazumder, A., Zhang, H. Z., & Rosenberg, S. A. (1982). Lymphokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J. Exp. Med., 155, 1823-1841.
12. Haeffner, A. C., Zepter, K., Elmets, C. A., & Wood, G. S. (1997). Analysis of tumor-infiltrating lymphocytes in cutaneous squamous cell carcinoma. Arch. Dermatol., 133, 585-590.
13. Hiraoka, A., Yamaguchi, M., Ohkubo, T., Kamamoto, T., Yoshida, Y., & Uchino, H. (1981). Effect of a streptococcal preparation, OK-432, on hematopoietic spleen colony formation in irradiated mice. Cancer Res., 41, 2594-2598.
14. Hoshino, T., Uchida, A., Iho, S., Kura, F., & Takahashi, T. (1986). Immunopharmacological aspect of OK-432 in the treatment of malignant disease with a special reference to an induction of autologous tumor killing activity. In G. Kelin and Uchida, A. (Eds). Univ. of Tokyo Press, Japan, pp. 5-15.
15. Ichimura, O., Suzuki, S., Saito, M., Sugawara, Y., & Ishida, N. (1985). Augmentation of interleukin 1 and interleukin 2 production by OK-432. Int. J. Immunopharmac., 7, 263-270.
16. Ikarashi, H., Fujita, K., Takakuwa, K., Kodama, S., Tokunaga, A., Takahashi, T., & Tanaka, K. (1994). Immunomodulation in patients with epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Cancer Res., 54, 190-196.
17. Ishii, Y., Uchiyama, Y., Hasegawa, S., Kinoshita, T., Mitsui, K., & Kojima, H. (1990). Detection of tumor necrosis factor/cachexia in pleural effusion of patients with lung cancer. Clin. Exp. Immunol., 80, 350-353.
18. Jabrane-Ferrat, N., Calvo, F., Faille, A., Lagabrielle, N., Boisson, A., Quillet, A., & Fradelizi, D. (1990). Recombinant gamma interferon provokes resistance of human breast cancer cells to spontaneous and IL-2 activated non-MHC restricted cytotoxicity. Br. J. Cancer, 61, 558-562.
19. Kato, K., Yamada, T., Kawahara, K., Onda, H., Asano, T., & Sagino, H. (1985). Purification and characterization recombinant human interleukin-2 produced in Escherichia coli. Biophys. Res., 31, 692-699.
20. Katsuta, S., Kaneko, Y., Tsutsui, K., Tamaki, S., Ibata, H., Chen, D. R., Suzuki, S., Natsuume-Sakai, S., & Yamamoto, A. (1989). Interleukin-1 inducing activity of a streptococcal preparation OK-432 and its fractions by human monocytes. J. Clin. Lab. Immunol., 28, 129-136.
21. Kinoshita, A., Suzuki, I., Sakurai, T., & Yadomae, T. (1992). Oral administration of a streptococcal agent OK-432 activates alveolar macrophages in mice. Int. J. Immunopharmac., 14, 205-211.
22. Lee, Y. C., Luh, S. P., Wu, R. M., & Lee, C. J. (1994). Adjuvant immunotherapy with intrapleural Streptococcus pyogenes (OK-432) in lung cancer patients after resection. Cancer, Immunol. Immunother., 39, 269-274.
23. Lozte, M. T., Grimm, E. A., Maunder, A., Strausser, J. L., & Rosenberg, S. A. (1981). Lysis of fresh and cultured autologous tumor by human lymphocytes cultured with T-cell growth factor. Cancer Res., 41, 4420-4425.
24. Luh, K. T., Yang, P. C., Kuo, S. H., Chang, D. B., Yu, C. J., & Lee, L. N. (1992). Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. Cancer, 69, 674-679.
25. Mandelboim, O., Berke, G., Fridkin, M., Feldman, M., Eisenstein, M., & Eisenbach, L. (1994). CTL induction by a tumor-associated antigen octapeptide derived from a murine lung carcinoma. Nature, 369, 67-71.
26. Quillet-Mary, A., Cavarec, L., Kermarrec, N., Marchiol-Fournigault, C., Gil, M. L., Conjeaud, H., & Fradelizi, D. (1991). Target lysis by human LAK cells is critically dependent upon target binding properties, but LFA-1, LFA-3 and ICAM-1 are not the major adhesion ligands on targets. Int. J. Cancer, 47, 473-479.
27. Saito, M., Ebina, T., Koi, M., Yamaguchi, T., Kawada, Y., & Ishida, N. (1982). Induction of interferon-γ in mouse spleen cells by OK-432, a preparation of Streptococcus pyogenes. Cell Immunol., 68, 187-192.
28. Sato, T. (1996). Active specific immunotherapy with hapten-modified autologous melanoma cell vaccine. Cancer, Immunol. Immunother., 43, 174-179.
29. Takahashi, K., Sone, S., Kimura, S., Ogura, T., & Monden, Y. (1993). Phenotypes and lymphokine activated killer activity of pleural cavity lymphocytes of lung cancer patients without malignant effusion. Chest, 103, 1732-1738.
30. Takahashi, K., Sone, S., Saito, S., Kamamura, Y., Uyama, T., Ogura, T., & Monden, Y. (1995). Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from pleural cavity mononuclear cells of lung cancer patients without malignant effusion. Jpn. J. Cancer Res., 86, 861-866.
31. Takahashi, K., Monden, Y., Saito, S., Kamamura, Y., & Uyama, T. (1996). Myasthenia gravis induces the activation and maturation of lymphocytes in thymoma. J. Clin. Immunol., 16, 190-197.
32. Takenoyama, M., Yasumoto, K., Harada, M., Matsuzaki, G., Ishida, T., Sugimachi, K., & Nomoto, K. (1996). Expression of activation-related molecules on regional lymph node lymphocyte in human lung cancer. Immunobiology, 195, 140-151.
33. Traversari, C., van der Bruggen, P., Luescher, I. F., Lurgquin, C., Chomez, P., Van Pel, A., De Plaen, E., Amar-Costesec, A., & Boon, T. (1992). A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytotoxic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med., 176, 1453-1457.
34. Uchida, A., & Micksche, M. (1981). In vitro augmentation of natural killer activity by OK-432. Int. J. Immunopharmac., 3, 365-375.
35. Wakasugi, H., Kasahara, T., Minato, N., Hamuro, J., Miyata, M., & Morioka, Y. (1982). In vitro potentiation of human natural killer cell activity by a streptococcal preparation, OK-432: interferon and interleukin-2 participation in the stimulation with OK-432. J. Natl. Cancer Ins., 69, 807-812.
36. Watanabe, Y., Hashizume, Y., Shimizu, J., Yoshida, M., Watanabe, S., Iwa, T., Sakai, S., Migaita, S., Sato, H., Murayama, T., Koshimura, S., & Saito, M. (1990). Functional character and augmentation of lymphocytes in regional lymph nodes of patients with lung cancer. Am. Rev. Respir. Dis., 142, 769-774.
37. Weiss, G. R., Margolin, K. A., Aronson, F. R., Sznol, M., Atkins, M. B., Kucher, J. P., Gaynor, E. R., Boldt, D. H., Doroshow, J. H., Bar, M. H., Hawkins, M. J., Demchak, P. A., Gucalp, R., & Fisher, R. (1992). A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J. Clin. Oncol., 10, 257-281.
38. Yagita, M., Itoh, K., Tsudo, K., Owen Schaub, L. B., Platsoucas, C. D., Balch, C. M., & Grimm, E. A. (1989). Involvement of both Tac and non-Tac Interleukin 2-binding peptides in the Interleukin 2-dependent proliferation of human tumor-infiltrating lymphocytes. Cancer Res., 49, 1154-1159.
39. Yamamoto, A., Nagamura, M., Usai, H., Sugawara, Y., Watanabe, N., Niitsu, Y., & Urushizaki, I. (1986). Release of tumor necrosis factor (TNF) into mouse peritoneal fluids by OK-432, a streptococcal preparation. Immunopharmacol., 11, 79-86.